Your browser is no longer supported. Please, upgrade your browser.
Settings
OTIC [NASD]
Otonomy, Inc.
Index- P/E- EPS (ttm)-1.18 Insider Own0.25% Shs Outstand52.34M Perf Week-16.48%
Market Cap106.30M Forward P/E- EPS next Y-0.91 Insider Trans-95.14% Shs Float48.20M Perf Month-19.49%
Income-44.70M PEG- EPS next Q-0.22 Inst Own76.80% Short Float2.85% Perf Quarter-63.20%
Sales0.30M P/S354.35 EPS this Y24.70% Inst Trans-1.90% Short Ratio1.16 Perf Half Y-51.52%
Book/sh1.27 P/B1.76 EPS next Y13.30% ROA-50.70% Target Price- Perf Year11.50%
Cash/sh1.81 P/C1.23 EPS next 5Y20.40% ROE-93.40% 52W Range1.90 - 6.98 Perf YTD-65.53%
Dividend- P/FCF- EPS past 5Y15.70% ROI-53.40% 52W High-68.07% Beta2.00
Dividend %- Quick Ratio8.00 Sales past 5Y- Gross Margin- 52W Low17.37% ATR0.18
Employees56 Current Ratio8.10 Sales Q/Q0.00% Oper. Margin- RSI (14)29.58 Volatility5.01% 5.77%
OptionableYes Debt/Eq0.23 EPS Q/Q42.70% Profit Margin- Rel Volume1.07 Prev Close2.20
ShortableYes LT Debt/Eq0.23 EarningsFeb 11 AMC Payout- Avg Volume1.19M Price2.23
Recom1.80 SMA20-16.71% SMA50-36.60% SMA200-45.41% Volume1,270,853 Change1.36%
Jun-01-20Resumed Oppenheimer Outperform $8
Dec-24-19Initiated Oppenheimer Outperform $8
Mar-19-18Downgrade JP Morgan Neutral → Underweight
Mar-12-18Upgrade Piper Jaffray Neutral → Overweight
Aug-30-17Downgrade Piper Jaffray Overweight → Neutral
Aug-30-17Downgrade JP Morgan Overweight → Neutral
Aug-15-17Upgrade JP Morgan Neutral → Overweight
Jun-02-17Initiated Piper Jaffray Overweight $32
May-26-16Initiated WallachBeth Buy $29
Aug-10-15Upgrade Bernstein Mkt Perform → Outperform
May-22-15Downgrade JP Morgan Overweight → Neutral
Apr-07-21 10:02PM  
04:06PM  
Apr-06-21 07:30AM  
Apr-05-21 07:30AM  
Mar-25-21 07:30AM  
Feb-26-21 11:01AM  
Feb-25-21 07:30AM  
Feb-22-21 09:32AM  
08:37AM  
07:23AM  
07:00AM  
Feb-17-21 07:30AM  
Feb-12-21 01:31AM  
Feb-11-21 04:17PM  
02:30PM  
Feb-04-21 07:30AM  
04:22AM  
Jan-05-21 07:30AM  
Dec-17-20 07:00AM  
Dec-15-20 07:50PM  
Dec-14-20 08:59AM  
Nov-30-20 07:30AM  
Nov-16-20 07:30AM  
Nov-06-20 09:03AM  
Nov-04-20 06:55PM  
05:03PM  
04:17PM  
02:30PM  
Oct-28-20 07:30AM  
Oct-02-20 07:30AM  
Sep-15-20 08:52AM  
Sep-10-20 08:41AM  
Sep-02-20 07:30AM  
Aug-17-20 03:30PM  
Aug-04-20 07:25PM  
04:22PM  
Aug-03-20 07:30AM  
Jul-28-20 04:05PM  
Jul-15-20 01:15PM  
Jul-13-20 04:01PM  
09:08AM  
Jul-09-20 09:00AM  
Jul-08-20 09:01PM  
Jul-07-20 10:44AM  
05:51AM  
Jul-06-20 04:04PM  
04:02PM  
Jun-30-20 11:42PM  
Jun-17-20 08:31AM  
Jun-15-20 04:05PM  
Jun-11-20 08:41AM  
07:30AM  
Jun-10-20 07:30AM  
Jun-08-20 07:30AM  
Jun-01-20 09:56AM  
May-28-20 08:32AM  
May-12-20 08:00AM  
May-07-20 07:30AM  
Apr-09-20 07:30AM  
Mar-26-20 06:47PM  
Mar-09-20 03:53PM  
Feb-27-20 07:25PM  
04:15PM  
Feb-24-20 07:30AM  
Feb-21-20 08:37AM  
Feb-20-20 07:30AM  
Jan-28-20 07:30AM  
Jan-23-20 07:30AM  
Jan-09-20 07:30AM  
Jan-07-20 12:31PM  
Jan-02-20 07:28AM  
Dec-24-19 07:24AM  
Dec-16-19 05:45AM  
Dec-03-19 08:51AM  
Nov-26-19 04:05PM  
Nov-22-19 07:11AM  
Nov-05-19 06:55PM  
04:13PM  
Oct-29-19 04:05PM  
11:23AM  
Oct-28-19 10:32AM  
Oct-01-19 07:30AM  
Sep-26-19 04:05PM  
Sep-17-19 07:30AM  
Aug-27-19 07:10AM  
Aug-01-19 04:20PM  
Jul-25-19 04:05PM  
Jul-11-19 12:33PM  
Jun-12-19 08:00AM  
May-14-19 05:47AM  
May-06-19 06:35PM  
05:31PM  
04:17PM  
02:30PM  
May-02-19 09:00AM  
07:30AM  
May-01-19 07:30AM  
Apr-29-19 04:05PM  
Apr-27-19 09:19AM  
Apr-11-19 07:30AM  
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Meniere's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lichter JayDirectorMar 03Sale2.70321,180866,5440Mar 03 08:06 PM
Lichter JayDirectorMar 02Sale2.90389,5741,129,375113,935Mar 02 07:51 PM
Lichter JayDirectorMar 01Sale2.86173,700496,087252,134Mar 02 07:51 PM
Lichter JayDirectorFeb 26Sale2.83330,554935,468313,753Mar 02 07:51 PM
Lichter JayDirectorFeb 25Sale2.95311,100918,989431,015Feb 25 09:56 PM
Lichter JayDirectorFeb 24Sale2.98503,1351,500,349541,376Feb 25 09:56 PM
Lichter JayDirectorFeb 23Sale2.89268,118774,325719,860Feb 25 09:56 PM